Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Eisai will partner with Abela Frères to market eribulin in Lebanon.
Eisai EMEA market development business unit vice president Toshitaka Asano noted that the launch of Halaven in Lebanon is part of Eisai’s wider strategy to establish a solid foundation in the EMEA region.
"Lebanon is an important market with specific healthcare needs and our valued partnership with Abela Frères will ensure that people with metastatic and locally advanced breast cancer have access to this additional and important treatment option," Asano added.